Alnylam Pharmaceuticals, Inc. (ALNY)
$
452.33
-1.85 (-0.41%)
Key metrics
Financial statements
Free cash flow per share
-0.4017
Market cap
59.3 Billion
Price to sales ratio
24.0828
Debt to equity
5.1760
Current ratio
2.8010
Income quality
0.0487
Average inventory
68.6 Million
ROE
-2.7421
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of innovative therapeutics based on ribonucleic acid interference. The company reported selling, general, and administrative expenses of $975,526,000.00 indicating its operational overhead costs. Additionally, the company incurred an interest expense of $141,858,000.00 reflecting its debt servicing obligations. A net loss of -$278,157,000.00 was reported, indicating challenges in its operations. With its stock identified by the symbol 'ALNY' in the market, the weighted average number of diluted shares outstanding is 127,651,000.00 reflecting potential dilution effects. Alnylam's pipeline of investigational RNAi therapeutics addresses a range of conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Marketed products such as ONPATTRO (patisiran), GIVLAARI, and OXLUMO highlight its commitment to addressing unmet medical needs. Furthermore, the company is advancing multiple candidates in its pipeline, including givosiran and cemdisiran, enhancing its portfolio with potential therapies for various diseases. Strategic collaborations with prominent partners like Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme bolster its development capabilities. The stock is priced at $315.75 positioning it in the higher-end market. It has an average trading volume of 1,074,731.00 indicating moderate liquidity. With a mid-range market capitalization of $59,290,964,070.00 the company is a steady performer in the competitive landscape. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth within the field. Alnylam continues to enhance its position through collaborations and partnerships, unlocking new avenues for discovering and delivering RNAi therapeutics. The company's focus on cutting-edge science and strategic alliances marks it as a noteworthy entity in advancing healthcare solutions and addressing complex diseases. As it navigates its challenges, Alnylam remains committed to its vision of transforming the treatment landscape through pioneering biopharmaceutical innovations.
Is Alnylam Pharmaceuticals, Inc. (ALNY) a good investment?
Investing in Alnylam Pharmaceuticals, Inc. (ALNY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Alnylam Pharmaceuticals, Inc. (ALNY)'s stock forecast?
Analysts predict Alnylam Pharmaceuticals, Inc. stock to fluctuate between $205.87 (low) and $469.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alnylam Pharmaceuticals, Inc.'s market capitalization?
As of 2025-08-29, Alnylam Pharmaceuticals, Inc.'s market cap is $59,290,964,070, based on 131,079,000 outstanding shares.
How does Alnylam Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alnylam Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alnylam Pharmaceuticals, Inc. (ALNY) stock?
To buy Alnylam Pharmaceuticals, Inc. (ALNY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALNY. Place an order (Market, Limit, etc.).
What is the best time to invest in Alnylam Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alnylam Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $2,248,243,000 | EPS: -$2.16 | Growth: -38.64%.
Where can I find Alnylam Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.alnylam.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alnylam Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Alnylam Pharmaceuticals, Inc. stock?
All-time high: $469.81 (2025-08-22) | All-time low: $117.58 (2022-05-12).
What are the key trends affecting Alnylam Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
seekingalpha.com
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pick-and-shovel' suppliers like Repligen, Illumina, and Twist Biosciences, which offer more stable financial prospects.
globenewswire.com
Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.
zacks.com
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
benzinga.com
Alnylam Pharmaceuticals Inc. ALNY reported upbeat second-quarter earnings and 2025 guidance on Thursday.
zacks.com
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
seekingalpha.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Poulton - CFO & Executive VP Pushkal P.
zacks.com
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and onl.
See all news
